Skip to main content
SpringerLink
Log in

Historical Perspective on the Early Studies of Posttransplant Lymphoproliferative Disorders (PTLD)

  • Chapter
Post-Transplant Lymphoproliferative Disorders

  • 871 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McKhann CF. Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation. 1969;8:209–12

    Article  PubMed  CAS  Google Scholar 

  2. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc. 1969;1(1):106–12

    PubMed  CAS  Google Scholar 

  3. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer. 1971;28(1):89–98

    Article  PubMed  CAS  Google Scholar 

  4. Penn I. Malignancies associated with immunosuppressive or cytotoxic therapy. Surgery. 1978;83(5):492–502

    PubMed  CAS  Google Scholar 

  5. Purtilo DT. Pathogenesis and phenotypes of an X-linked recessive lymphoproliferative syndrome. Lancet. 1976;2(7991):882–5

    Article  PubMed  CAS  Google Scholar 

  6. Purtilo DT, DeFlorio D Jr., Hutt LM, et al. Variable phenotypic expression of an X-linked recessive lymphoproliferative syndrome. N Engl J Med. 1977;297(20):1077–80

    Article  PubMed  CAS  Google Scholar 

  7. Spector BD, Perry GS, III, Kersey JH. Genetically determined immunodeficiency diseases (GDID) and malignancy: report from the immunodeficiency—cancer registry. Clin Immunol Immunopathol. 1978;11(1):12–29

    Article  PubMed  CAS  Google Scholar 

  8. Matas AJ, Simmons RL, Najarian JS. Chronic antigenic stimulation, herpesvirus infection, and cancer in transplant recipients. Lancet. 1975;1(7919):1277–9

    Article  PubMed  CAS  Google Scholar 

  9. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein—Barr virus, immunodefi-ciency, and B cell lymphoproliferation. Transplantation. 1985;39(5):461–72

    Article  PubMed  CAS  Google Scholar 

  10. Epstein MA, Achong B. The Epstein—Barr virus. New York: Springer; 1979

    Book  Google Scholar 

  11. Rosen A, Gergely P, Jondal M, Klein G, Britton S. Polyclonal Ig production after Epstein—Barr virus infection of human lymphocytes in vitro. Nature. 1977;267(5606):52–4

    Article  PubMed  CAS  Google Scholar 

  12. Robinson JE, Brown N, Andiman W, et al. Diffuse polyclonal B-cell lymphoma during primary infection with Epstein—Barr virus. N Engl J Med. 1980;302(23):1293–7

    Article  PubMed  CAS  Google Scholar 

  13. Henle G, Henle W. The virus as the etiologic agent of infectious mononucleosis. In: Epstein M, Achong B, editors. The Epstein—Barr virus. New York: Springer; 1979. p. 297–320

    Chapter  Google Scholar 

  14. Frank A, Andiman WA, Miller G. Epstein–Barr virus and nonhuman primates: natural and experimental infection. Adv Cancer Res. 1976;23:171–201

    Article  PubMed  CAS  Google Scholar 

  15. Klein G. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Acad Sci USA. 1979;76(5):2442–6

    Article  PubMed  CAS  Google Scholar 

  16. Epstein MA, Achong BG. Introduction: discovery and general biology of the virus. In: Epstein MA, Achong BG, editors. The Epstein—Barr virus. New York: Springer; 1979. p. 1–22

    Chapter  Google Scholar 

  17. Klein E, Masucci MG. Cell-mediated immunity against Epstein—Barr virus infected B lymphocytes. Springer Semin Immunopathol. 1982;5(1):63–73

    PubMed  CAS  Google Scholar 

  18. Chang RS, Lewis JP, Reynolds RD, Sullivan MJ, Neuman J. Oropharyngeal excretion of Epstein—Barr virus by patients with lymphoproliferative disorders and by recipients of renal homografts. Ann Intern Med. 1978;88(1):34–40

    Article  PubMed  CAS  Google Scholar 

  19. Strauch B, Andrews LL, Siegel N, Miller G. Oropharyngeal excretion of Epstein—Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet. 1974;1(7851):234–7

    Article  PubMed  CAS  Google Scholar 

  20. Chang RS, Lewis JP, Abildgaard CF. Prevalence of oropharyngeal excreters of leukocyte-transforming agents among a human population. N Engl J Med. 1973;289(25):1325–9

    Article  PubMed  CAS  Google Scholar 

  21. Cheeseman SH, Henle W, Rubin RH, et al. Epstein—Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon. Ann Intern Med. 1980;93(1):39–42

    Article  PubMed  CAS  Google Scholar 

  22. Marker SC, Ascher NL, Kalis JM, Simmons RL, Najarian JS, Balfour HH Jr. Epstein—Barr virus antibody responses and clinical illness in renal transplant recipients. Surgery. 1979;85(4):433–40

    PubMed  CAS  Google Scholar 

  23. Hertel B, Rosai J, Dehner P, Simmons R. Lymphoproliferative disorders in organ transplant recipients. Lab Invest. 1977;36:340

    Google Scholar 

  24. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res. 1981;41(11 Pt 1):4262–79

    PubMed  CAS  Google Scholar 

  25. Hanto DW, Frizzera G, Gajl-Peczalska J, et al. The Epstein—Barr virus (EBV) in the pathogen-esis of posttransplant lymphoma. Transplant Proc. 1981;13(1 Pt 2):756–60

    PubMed  CAS  Google Scholar 

  26. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein—Barr virus. Cancer Res. 1981;41 (11 Pt 1):4253–61

    PubMed  CAS  Google Scholar 

  27. Hanto DW, Gajl-Peczalska KJ, Frizzera G, et al. Epstein—Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann Surg. 1983;198(3):356–69

    Article  PubMed  CAS  Google Scholar 

  28. Hanto DW, Sakamoto K, Purtilo DT, Simmons RL, Najarian JS. The Epstein—Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Clinical, pathologic, and viro-logic correlation. Surgery. 1981;90(2):204–13

    PubMed  CAS  Google Scholar 

  29. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979;2(8151):1033–6

    Article  PubMed  CAS  Google Scholar 

  30. Nagington J, Gray J. Cyclosporin A immunosuppression, Epstein—Barr antibody, and lymphoma. Lancet. 1980;1(8167):536–7

    Article  PubMed  CAS  Google Scholar 

  31. Crawford DH, Thomas JA, Janossy G, et al. Epstein—Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet. 1980;1(8182):1355–6

    Article  PubMed  CAS  Google Scholar 

  32. Weintraub J, Warnke RA. Lymphoma in cardiac allotransplant recipients. Clinical and histo-logical features and immunological phenotype. Transplantation. 1982;33(4):347–51

    Article  PubMed  CAS  Google Scholar 

  33. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1(8377):583–7

    Article  PubMed  CAS  Google Scholar 

  34. Cleary ML, Warnke R, Sklar J. Monoclonality of lymphoproliferative lesions in cardiac-transplant recipients. Clonal analysis based on immunoglobulin-gene rearrangements. N Engl J Med. 1984;310(8):477–82

    Article  PubMed  CAS  Google Scholar 

  35. Cleary ML, Sklar J. Lymphoproliferative disorders in cardiac transplant recipients are multi-clonal lymphomas. Lancet. 1984;2(8401):489–93

    Article  PubMed  CAS  Google Scholar 

  36. Hanto DW, Birkenbach M, Frizzera G, Gajl-Peczalska KJ, Simmons RL, Schubach WH. Confirmation of the heterogeneity of posttransplant Epstein—Barr virus-associated B cell proliferations by immunoglobulin gene rearrangement analyses. Transplantation. 1989;47(3):458–64

    Article  PubMed  CAS  Google Scholar 

  37. Saemundsen AK, Purtilo DT, Sakamoto K, et al. Documentation of Epstein—Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein— Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res. 1981;41(11 Pt 1):4237–42

    PubMed  CAS  Google Scholar 

  38. Saemundsen AK, Klein G, Cleary M, Warnke R. Epstein—Barr-virus-carrying lymphoma in cardiac transplant recipient. Lancet. 1982;2(8290):158

    Google Scholar 

  39. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein—Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med. 1982;306(15):913–8

    Article  PubMed  CAS  Google Scholar 

  40. Shapiro RS, Chauvenet A, McGuire W, et al. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med. 1988;318(20):1334

    Article  PubMed  CAS  Google Scholar 

  41. Kane RE, Bunchman TE, Vogler C, Brems JJ. Treatment of a B-cell lymphoproliferative disorder in a liver transplant patient with interferon alpha and gamma globulin. A case report. Clin Transplant. 1992;6:154–8

    Google Scholar 

  42. Hanto DW, Frizzera G, Gajl-Peczalska J, Balfour HH, Jr., Simmons RL, Najarian JS. Acyclovir therapy of Epstein—Barr virus-induced posttransplant lymphoproliferative diseases. Transplant Proc. 1985;17:89–92

    Google Scholar 

  43. Hanto DW. Classification of Epstein—Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med. 1995;46:381–94

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Transplantation, The Transplant Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, 7th Floor, Boston, MA, 02215, USA

    Douglas W. Hanto

Authors
  1. Douglas W. Hanto
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pediatric Kidney Transplantation, Shands Hospital at UF, University of Florida College of Medicine Medical Director, Gainesville, Florida, USA

    Vikas R. Dharnidharka (Associate Professor and Chief Fellowship Program Director Division of Pediatric Nephrology) (Associate Professor and Chief Fellowship Program Director Division of Pediatric Nephrology)

  2. Division of Infectious Diseases Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

    Michael Green (Professor of Pediatrics and Surgery) (Professor of Pediatrics and Surgery)

  3. Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

    Steven A. Webber (Professor of Pediatrics, Chief, Division of Cardiology Co-Director, Heart Center Medical Director, Pediatric Heart and Heart-Lung Transplantation) (Professor of Pediatrics, Chief, Division of Cardiology Co-Director, Heart Center Medical Director, Pediatric Heart and Heart-Lung Transplantation)

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hanto, D.W. (2010). Historical Perspective on the Early Studies of Posttransplant Lymphoproliferative Disorders (PTLD). In: Dharnidharka, V.R., Green, M., Webber, S.A. (eds) Post-Transplant Lymphoproliferative Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01653-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01653-0_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01652-3

  • Online ISBN: 978-3-642-01653-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation